Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

2.210 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.210
Bid (Size) 2.140 (100)
Ask (Size) 2.550 (100)
Prev. Close 2.210
Today's Range 2.210 - 2.210
52wk Range 1.070 - 3.100
Shares Outstanding 80,817,079
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProQR to Participate in 8th Annual Evercore Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Third Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
-19.3%
-19.3%
1 Month
+0.5%
+0.5%
3 Month
+2.3%
+2.3%
6 Month
+8.9%
+8.9%
1 Year
-17.2%
-17.2%

More News

Read More
News headline image
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
ProQR to Participate in Upcoming Investor Conferences in October 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
ProQR Announces Second Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Presentation at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Year End 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
ProQR Announces Third Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
Via Benzinga
News headline image
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
From ProQR Therapeutics N.V.
Via GlobeNewswire

Frequently Asked Questions

Is ProQR Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, ProQR Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does ProQR Therapeutics N.V. - Ordinary Shares trade on?
ProQR Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares?
The ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares is PRQR on the Nasdaq Stock Market
What is the current price of ProQR Therapeutics N.V. - Ordinary Shares?
The current price of ProQR Therapeutics N.V. - Ordinary Shares is 2.210
When was ProQR Therapeutics N.V. - Ordinary Shares last traded?
The last trade of ProQR Therapeutics N.V. - Ordinary Shares was at 12/23/25 04:00 PM ET
What is the market capitalization of ProQR Therapeutics N.V. - Ordinary Shares?
The market capitalization of ProQR Therapeutics N.V. - Ordinary Shares is 178.61M
How many shares of ProQR Therapeutics N.V. - Ordinary Shares are outstanding?
ProQR Therapeutics N.V. - Ordinary Shares has 179M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.